Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Humana (HUM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana (NYSE: HUM) is currently riding a wave of positive momentum. The stock has been on a five-day continuous winning streak, delivering cumulative gains of 13% and adding approximately $4.0 billion in value.
A U.S. judge on Tuesday rejected Humana's bid to challenge the Centers for Medicare & Medicaid Services' 2025 ratings for its Medicare Advantage programs, which could cost the company millions in bonus payments from the government.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana's stock spiked after the health insurer disclosed some findings from the government's Star Ratings for its 2026 Medicare Advantage plans.
HUM gains from rising premiums, Medicare growth and CenterWell expansion, but faces pressure from high benefit ratios and costs.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana (HUM) reported earnings 30 days ago. What's next for the stock?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HUM partners with DrFirst to increase statin use in high-risk patients with diabetes and cardiovascular disease, aiming to close care gaps.